Short answer · Medically reviewed summary · Last updated: 2026-05-08
Primary Sclerosing Cholangitis (PSC) is a chronic, rare liver disease characterized by inflammation and scarring of the bile ducts, which restricts bile flow and can lead to liver damage. While the exact cause remains unknown, it is widely considered an immune-mediated condition that often occurs alongside inflammatory bowel disease (IBD). What is Primary Sclerosing Cholangitis? Primary Sclerosing Cholangitis is a progressive disorder where the body’s immune system mistakenly attacks the bile ducts, both inside and outside the liver.
What is Primary Sclerosing Cholangitis
What is Primary Sclerosing Cholangitis? Plain-language, medically reviewed definition plus the lived reality told by patients.
Primary Sclerosing Cholangitis (PSC) is a chronic, rare liver disease characterized by inflammation and scarring of the bile ducts, which restricts bile flow and can lead to liver damage. While the exact cause remains unknown, it is widely considered an immune-mediated condition that often occurs alongside inflammatory bowel disease (IBD).
What is Primary Sclerosing Cholangitis?
Primary Sclerosing Cholangitis is a progressive disorder where the body’s immune system mistakenly attacks the bile ducts, both inside and outside the liver. This persistent inflammation causes the ducts to narrow and scar, eventually leading to a buildup of bile in the liver (cholestasis), which can cause cirrhosis over time. Currently, 36 members of the DiseaseMaps.org community are living with and sharing their experiences with this condition.
Which body systems are affected?
Primary Sclerosing Cholangitis primarily impacts the digestive system and the immune system. The narrowing of the bile ducts disrupts digestion, leading to symptoms such as jaundice, weight loss, and nausea. Because the disease is closely linked to the immune system, many patients also experience systemic fatigue and complications related to the gallbladder or pancreas.
Who is typically affected by Primary Sclerosing Cholangitis?
While Primary Sclerosing Cholangitis can affect anyone, it is most commonly diagnosed in adults between the ages of 30 and 50. Data indicates a slight male predominance. Key facts that distinguish this condition include:
- Strong Association with IBD: Approximately 70–80% of patients with Primary Sclerosing Cholangitis also have inflammatory bowel disease, most commonly ulcerative colitis.
- Clinical Presentation: Unlike typical liver infections, Primary Sclerosing Cholangitis involves chronic, "sclerosing" (hardening) of the ducts.
- Progression: The rate of disease progression is highly variable, ranging from stable for many years to requiring a liver transplant.
How is Primary Sclerosing Cholangitis managed?
There is currently no cure for Primary Sclerosing Cholangitis, so treatment focuses on managing symptoms and monitoring for complications. Common management strategies include:
- Ursodeoxycholic acid (Ursodiol) to improve bile flow.
- Cholestrim powder or other medications to manage intense itching (pruritus).
- Monitoring for biliary strictures, which may be treated with endoscopic procedures.
- Liver transplantation in advanced cases of liver failure.
Next steps
- Consult a hepatologist or gastroenterologist specializing in cholestatic liver diseases.
- Connect with the 36 members of the DiseaseMaps.org community to share support and lived experiences.
- Discuss current clinical trials for new therapies with your medical team.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Primary Sclerosing Cholangitis
- Orphanet: Primary Sclerosing Cholangitis (ORPHA:794)
- American Association for the Study of Liver Diseases (AASLD) Practice Guidance
- OMIM (Online Mendelian Inheritance in Man): PSC entry #600837
